Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ashish Sanil"'
Autor:
HS Han, Christina Yau, Jane Perlmutter, Amy Wilson, Heather Beckwith, Anne M. Wallace, Tara Sanft, Ashish Sanil, Erica Stringer-Reasor, Laura J. Esserman, Zahi Mitri, Donald A. Berry, Rita Nanda, Claudine Isaacs, Alexandra Thomas, Kevin Kalinsky, Hope S. Rugo, Michelle E. Melisko, A. Jo Chien, Smita Asare, W. Fraser Symmans, Judy C. Boughey, Douglas Yee, Laura J. van't Veer, Kathy S. Albain, Amy S. Clark, Julie E. Lang, Anthony D. Elias, Nola M. Hylton, Angela DeMichele, Shi Wei, Richard Schwab
Publikováno v:
Cancer Research. 81:PD1-10
Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint (MP) risk to evaluate novel agents as neoadjuvant therapy for women with high-risk stage II/
Autor:
Jane Perlmutter, Gillian L. Hirst, A. Jo Chien, Anthony D. Elias, Andres Forero-Torres, Kevin Kalinsky, Julia Wulfkuhle, Ruby Singhrao, Lajos Pusztai, Nola M. Hylton, Richard Schwab, Smita Asare, Laura Sit, Hope S. Rugo, M. Melisko, Judy C. Boughey, Laura J. Esserman, Angela DeMichele, Laura J. van't Veer, Rebecca Shatsky, Scott M. Berry, Lili Du, Christina Yau, Ashish Sanil, D Yee, Adam Asare, Donald A. Berry, Kathy S. Albain, Amy S. Clark, Anne M. Wallace, Rita Nanda, Claudine Isaacs, Hyo S. Han, Denise M. Wolf, E. Petricoin, Minetta C. Liu, Teresa L. Helsten, Jeffrey B. Matthews, Amy Wilson, Erica Stringer-Reasor, Alexandra Thomas, W. Fraser Symmans, Heather Beckwith, Kathleen Kemmer, Lamorna Brown-Swigart
Publikováno v:
SSRN Electronic Journal.
The combination of PD-L1-inhibitor durvalumab and PARP-inhibitor olaparib (DOP) in addition to standard neoadjuvant chemotherapy was investigated in the phase II I-SPY2 platform trial of stage II/III HER2-negative breast cancer. Seventy-three HER2-ne
Autor:
Hope S. Rugo, Richard Schwab, Minetta C. Liu, Christina Yau, Ashish Sanil, Scott M. Berry, Marie C Lee, Katherine Steeg, Amy Wilson, A. Jo Chien, Rita Nanda, Claudine Isaacs, Angela DeMichele, Teresa Helsten, Jane Perlmutter, Judy C. Boughey, Michelle E. Melisko, Douglas Yee, Erica Stringer-Reasor, Gillian L. Hirst, Kathy S. Albain, Erin D. Ellis, Laura van 't Veer, Ronald N. Cohen, Amy S. Clark, W. Fraser Symmans, Anne M. Wallace, Andres Forero-Torres, Rebecca Shatsky, Catherine Parker, Anthony D. Elias, Nola M. Hylton, Donald A. Berry, Smita Asare, Laura J. Esserman, Kathleen Kemmer, Adam Asare, Ruby Singhrao, HS Han, Tufia C. Haddad, Nora Jaskowiak, Melanie Catherine Majure, Jeffrey B. Matthews, Lajos Pusztai
Publikováno v:
JAMA Oncol
Importance Approximately 25% of patients with early-stage breast cancer who receive (neo)adjuvant chemotherapy experience a recurrence within 5 years. Improvements in therapy are greatly needed. Objective To determine if pembrolizumab plus neoadjuvan
Autor:
Angela DeMichele, Teresa Helsten, Stephen Y. Chui, Christina Yau, Lajos Pusztai, Kathy S. Albain, W. Fraser Symmans, Ashish Sanil, Melissa Paoloni, Rebecca K. Viscusi, Anthony D. Elias, Sarah E. Davis, Debasish Tripathy, Kirsten K. Edmiston, Julia Lyandres, Nola M. Hylton, Laura J. Esserman, Michael Hogarth, Donald W. Northfelt, Laura J. van't Veer, Donald A. Berry, Meredith Buxton, Jane Perlmutter, A. Jo Chien, Gillian L. Hirst, John W. Park, Judy C. Boughey, Henry G. Kaplan, Minetta C. Liu, Stacy L. Moulder, Douglas Yee, Qamar J. Khan, Julie E. Lang, David M. Euhus, Tufia C. Haddad, William C. Wood, Richard Schwab, Michelle E. Melisko, Rita Nanda, Claudine Isaacs, Anne M. Wallace, Kathleen Kemmer, Barbara Haley
BackgroundThe heterogeneity of breast cancer makes identifying effective therapies challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-risk clinical stage II or III breast cancer, evaluated multiple n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68b556d1a9a91a81ff185979e54f23a4
https://europepmc.org/articles/PMC5259558/
https://europepmc.org/articles/PMC5259558/